Home | Welcome to Contract Pharma   
Last Updated Sunday, October 26 2014
Print

GSK Discontinues Development of Anacor Drug



Published October 5, 2012
Related Searches: R&D Clinical Trial Development
GlaxoSmithKline has discontinued development of GSK2251052 following a recent clinical trial that was stopped due to the identification of microbiological findings of resistance in a small number of patients undergoing treatment of complicated urinary tract infections (cUTI). GSK has decided to discontinue further development of GSK2251052 and return all rights to Anacor.
 
Anacor Pharmaceuticals licensed the drug to GSK in July 2010 under an ongoing R&D collaboration. GSK is continuing to fund Anacor’s research activities in tuberculosis as under the companies’ amended R&D collaboration.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On